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Abstract: Pharmacological agents suggested for infarct size limitation have serious side 
effects when used at cardioprotective doses which hinders their translation into clinical 
practice. The solution to the problem might be direct delivery of cardioprotective drugs into 
ischemic-reperfused myocardium. In this study, we explored the potential of silica nanoparticles 
for passive delivery of adenosine, a prototype cardioprotective agent, into ischemic-reperfused 
heart tissue. In addition, the biodegradation of silica nanoparticles was studied both in vitro and in 
vivo. Immobilization of adenosine on the surface of silica nanoparticles resulted in enhancement 
of adenosine-mediated infarct size limitation in the rat model. Furthermore, the hypotensive 
effect of adenosine was attenuated after its adsorption on silica nanoparticles. We conclude 
that silica nanoparticles are biocompatible materials that might potentially be used as carriers 
for heart-targeted drug delivery.
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Introduction
Myocardial infarction is a major cause of morbidity and mortality worldwide. The 
advent of reperfusion strategies such as thrombolysis and percutaneous coronary 
intervention has resulted in significant improvement in survival and prognosis in 
patients with myocardial infarction. Along with the apparent favorable effects, 
reperfusion therapy has brought to light the problem of irreversible reperfusion injury, 
which is usually lethal.1 According to different estimates, acute reperfusion injury 
in patients treated with primary percutaneous coronary intervention can increase 
myocardial infarct size by 20%–50%.2 Therefore, it follows that prevention and/or 
alleviation of myocardial ischemia-reperfusion injury is one of the most important 
goals of medical care. One of the promising approaches for reducing cardiac 
ischemia-reperfusion injury is ischemic postconditioning, a phenomenon of infarct 
size reduction caused by induction of repetitive brief episodes of ischemia during early 
reperfusion after a prolonged ischemic insult.3,4 In recent years, it has been shown both 
in the experimental and clinical settings that the infarct-limiting effect of ischemic 
postconditioning can be mimicked by administration of certain cardioprotective drugs at 
the time of myocardial reperfusion or just prior to it.5 This phenomenon has been termed 
“pharmacological postconditioning”. However, it should be noted that the agents used 
for pharmacological postconditioning may have serious side effects when used at the 
doses required for infarct size limitation, which hinders their translation into the clinical 
realm.1 One solution to this problem might be direct delivery of cardioprotective drugs 
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into the ischemic-reperfused myocardium. This approach, 
known as “targeted drug delivery”, offers major advantages 
as compared with systemic drug distribution, ie, reduced 
toxicity owing to selective drug accumulation in the target 
area and increased therapeutic efficacy of the drug.6
There are two basic principles suggested for targeted drug 
delivery into affected tissue using nanosized carriers. The first 
is usually referred to as “passive targeting”, suggesting that 
the drug-loaded nanocarrier is passively retained in areas with 
increased microvascular permeability.7,8 The second is known 
as “active targeting”, which may result in an even greater 
gradient of drug concentration between the intact and injured 
tissue due to the specific interaction of the tissue-recognition 
ligand engrafted on the surface of the carrier and a unique 
disease marker expressed either on the cell membrane or 
inside the cell.9 This interaction results in accumulation of 
the drug-enriched nanocarrier in the tissue of interest with 
subsequent release of the drug during biodegradation of the 
particle coating.
Much of the work on targeted drug delivery has been 
in the field of cancer treatment. At present, there is some 
(albeit limited) published evidence that the ischemic heart 
can be actively and passively targeted with drug-loaded 
liposomes.10,11 Other nanoparticles, including inorganic ones, 
also hold promise for drug delivery targeted to the heart. We 
have previously shown that 6–13 nm silica nanoparticles are 
not toxic during acute intravenous administration and can 
also be readily functionalized by immobilization or chemical 
assembly approaches.12
Although  recent  research  has  made  significant 
strides in clarifying the mechanisms of endogenous and 
pharmacological cardioprotection, we still do not have an 
“ideal” cardioprotective agent with a favorable safety and 
efficacy profile. There is now considerable evidence for 
involvement of adenosine in the mechanism(s) of ischemic 
postconditioning-induced cardiac protection. In particular, 
the protective effect of ischemic postconditioning in the 
isolated rabbit heart was abolished after administration 
of DPCPX, a selective adenosine A1 receptor blocker.13 
Genetic deletion of A1 and A2a receptors attenuated the 
cardioprotective effects of ischemic postconditioning.14,15 
Furthermore, exogenous infusion of NECA, a nonselective 
A1/A2 receptor agonist,16 and CGS-21680, a selective A2a 
receptor agonist,17 immediately after prolonged ischemia 
had a pronounced infarct-limiting effect in the isolated rat 
heart and in vivo rabbit model, respectively. Taken together, 
these experimental data strongly suggest that adenosine can 
exhibit a potent cardioprotective effect when administered 
at the onset of myocardial reperfusion. However, clinical use 
of adenosine for myocardial protection is limited because of 
side effects, such as hypotension and bradycardia.
The present study investigated the potential of silica 
nanoparticles for delivery of adenosine, a prototype 
cardioprotective agent, into the ischemic-reperfused heart. 
Only a passive targeting strategy could be used, so we 
compared the infarct-limiting and hemodynamic effects of 
free adenosine with those of adenosine immobilized on the 
surface of silica nanoparticles. Further, biodegradation of 
silica nanoparticles was studied both in vitro and in vivo.
Materials and methods
Characteristics of silica nanoparticles  
and adenosine immobilization
Highly dispersed standard pyrogenic silica (Aerosil® A380, 
Vekton, St Petersburg, Russia) was used throughout the 
experiments. The surface area of the silica nanoparticles was 
determined using the Brunauer–Emmett–Teller method and 
averaged 170–380 m2/g. The mean particle diameter varied 
from 6 nm to 13 nm. Prior to preparation of the aqueous 
suspensions, the silica nanoparticles were sterilized at 180°C 
for 3 hours. Adsorption of adenosine onto the surface of the 
silica nanoparticles was achieved by mixing the suspension 
of silica nanoparticles in sterile apyrogenic 0.9% sodium 
chloride and adenosine solution in the same vehicle. The 
samples were then subjected to 10 minutes of sonication and 
left at +4°C overnight.
Adsorption efficiency was determined by spectrophoto-
metric measurement (UV-2450, Shimadzu, Japan) of residual 
adenosine concentration in the solution after completion of 
adsorption. For adsorption studies, 6.9 mg of adenosine was 
dissolved in 1 mL of distilled water followed by the addition of 
20 mg of silica nanoparticles and left for different time   intervals. 
After that, the volume of the sample was adjusted to 9 mL and 
centrifuged at 10000 g for 3 minutes. Centrifuged solution 
was further diluted and analyzed   spectrophotometrically. The 
spectra were registered at λ = 260 nm in quartz cuvettes. The 
optical length was selected empirically to achieve an optical 
density of 0.1–1.0 at maximal absorption (ν = 38.6 × 103 cm–1, 
which corresponds to λ = 260 nm).
Biodegradation of silica nanoparticles
Biodegradation of the silica nanoparticles was studied 
both in vitro and in vivo. When designing the experiments, 
we   speculated that the nanoparticles were undergoing 
biodegradation due to gradual erosion of their surface, result-
ing in formation of water-soluble salts of silicic acid which 
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are excreted by the kidney (Figure 1). Suspension of Aerosil 
A380 in Krebs–Henseleit buffer with an electrolyte composi-
tion similar to that of plasma with a final concentration of 
silica nanoparticles of 2 mg/mL and pH 7.4 was used for 
the in vitro biodegradation study. The experiments were 
performed under continuous stirring in a 100 mL polytetra-
fluoroethylene container. The temperature of the media was 
maintained at 37°C by water jacketing. The samples were 
continuously gassed with carbogen (95% O2 and 5% CO2). 
Total incubation time was 15 hours. Samples were taken at 
5-hourly intervals and analyzed for silicate content spectro-
photometrically after reaction with molybdenum blue at a 
wavelength of 815 nm in 1 cm layer cuvettes.
In vivo silica nanoparticle biodegradation was studied 
in male Wistar rats weighing 200–250 g. The animals were 
fed regular chow, and water was available ad libitum. All 
experiments were performed in accordance with the Guide 
for the Care and Use of Laboratory Animals and approved 
by the local ethics committee. The animals were anesthetized 
with sodium pentobarbital, given intraperitoneally at a 
dose of 60 mg/kg. The silica nanoparticles were infused 
intravenously at a dose of 2 mg/mL and a volume of 1 mL, 
followed by sampling of the liver at one hour, and 10, 20, 
and 30 days after infusion (n = 3–6 at each time point). 
Animals that received an intravenous infusion of 1 mL of 
vehicle (n = 8) served as controls. Liver samples were dried 
at 90°C for 24 hours to obtain a constant weight. The liver 
was chosen for sampling and analysis on the basis of previous 
biodistribution experiments showing maximal accumulation 
of silica in this organ.12 Quantitative analysis of silicon content 
within the samples was performed using atomic absorption 
spectroscopy. The product of mineralization obtained after 
drying was analyzed by atomic absorption spectrometry with 
electrothermic atomization and Zeeman correction. Silicon 
content within the product of mineralization was recalculated 
for the dry sample weight and expressed in µg/g.
Biodistribution of silica nanoparticles with   
and without myocardial ischemia
For investigation of passive heart-targeted drug delivery using 
silica nanoparticles, we first studied the biodistribution of 
unmodified nanoparticles in rats with regional myocardial 
ischemia-reperfusion injury. Male Wistar rats weighing 
200–250 g were anesthetized with sodium pentobarbital 
60 mg/kg and used throughout the experiments. The animals 
were randomly allocated to one of three groups, ie, controls 
(n = 5, intravenous infusion of saline), animals treated with 
silica nanoparticles (2 mg/mL, 1 mL intravenously) and a 
sham surgical procedure (n = 6), and animals treated with 
silica nanoparticles and myocardial ischemia-reperfusion 
injury (n = 5). Under mechanical ventilation, regional myo-
cardial ischemia was induced by 30 minutes of left coronary 
artery ligation followed by 60 minutes of reperfusion. The 
silica nanoparticles were infused for 10 minutes, starting 
5 minutes prior to reperfusion. The left ventricle of the heart 
and the liver were sampled at the end of the experiments, then 
rinsed and dried at 90°C for 24 hours to obtain a constant 
weight. Determination of the silicon content in the organ 
SNP Adenosine-
loaded SNP
Renal excretion
Water-soluble silicic
acid salts
(Me − K, Na, Ca)
Gradual surface
erosion
Mex(SiO3)Y
MexSiO4
Accumulation in the ischemic-
reperfused myocardium,
adenosine release
Intravenous infusion
Figure 1 Proposed algorithm of passive heart targeting with silica nanoparticles. 
Abbreviation: SNP, silica nanoparticles.
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samples was done using atomic absorption spectroscopy 
as described above. Direct evidence of the effectiveness of 
targeted drug delivery can be obtained only by measuring 
drug concentration in target tissue. However, this is not 
feasible with adenosine, which has a half-life of less than 
10 seconds in blood.18
Hemodynamic effects of nanoparticle-
bound and free adenosine
Adenosine bound to silica nanoparticles was administered 
to the anesthetized rats intravenously for 10 minutes at a 
dose of 300 µg/kg/minute (n = 6). Control animals received 
a 10-minute intravenous infusion of adenosine at a dose of 
300 µg/kg/minute (n = 8). Mean blood pressure was regis-
tered in the common carotid artery before the beginning of 
drug infusion, at minutes 5 and 10 of infusion, and at minutes 
5 and 10 of recovery.
Effects of nanoparticle-bound and free 
adenosine on infarct size
Five minutes prior to the end of 30 minutes of ischemia, the 
anesthetized animals received either a 10-minute adenosine 
infusion at a dose of 300 µg/kg/minute (n = 5) or an infusion of 
adenosine adsorbed onto silica nanoparticles at the equivalent 
dose (n = 6). Control animals were treated with vehicle (n = 8). 
The left coronary artery was reoccluded after 90 minutes 
of reperfusion, followed by administration of 0.5 mL of 
5% Evans Blue (MP Biomedicals, Santa Ana, CA) via the 
femoral vein for identification of the area at risk. The hearts 
were excised and cut into five 2 mm thick slices parallel to 
the atrioventricular groove. The basal surface of each slice was 
digitally photographed. The slices were immersed in a 1% 
solution of 2,3,5-triphenyltetrazolium chloride at 37°C (pH 7.4) 
for 15 minutes and photographed again for identification of 
infarct area. The images were digitized using Adobe Photoshop 
CS. The area at risk was expressed as a percentage of the 
whole slice, and the infarct area was expressed as a percentage 
of the area at risk. Values of area at risk and infarct area 
for each heart were obtained by summarizing data for the 
slices and calculating mean values. Statistical analyses were 
performed using the nonparametric Mann–Whitney U test, with 
P values ,0.05 considered to be statistically significant.
Results
Effectiveness of adenosine adsorption 
onto silica nanoparticles
The adenosine content on the surface of the silica nanopar-
ticles was 0.017 mmoL/g, while adsorption efficiency was 
4.5 mg/g. Complete adsorption of adenosine on the silica 
nanoparticle surface was achieved within 15 minutes.
Biodegradation of silica nanoparticles  
in vitro and in vivo
Results of analyses of samples obtained in the in vitro 
experiments are shown on Figure 2. As a rule, physical or 
chemical processes of this kind (eg, material aging, changes 
in relative surface area, dissolution) are asymptotic and might 
be adequately described by the following inverse polynomial 
of the second degree:
 D  = a + b/(T + 1) + c/(T + 1)2  (1)
where D is relative optical density, T is time (days), and a, 
b, and c are coefficients of the polynomial.
Because the relative optical density in the analytical 
method used is linearly correlated with the concentration of 
silicate ion, the changes of the latter could also be described 
by equation (1). In this case, changes in the silicate concentra-
tion with time in the samples investigated might be described 
by equation (1) with the following coefficients:
 a  = 0.0224195 
  b = −0.0479528 
  c = 0.0255494 
(2)
Coefficient a is the maximal theoretically possible relative 
optical density in this process and hence is proportional to 
the maximal concentration of silicate. Using inverse recom-
putation according to equation (1), it is possible to derive the 
value which corresponds to 95% biodegradation of silica, 
which is 41 days. These data fit well with the results of Finnie 
et al19 who studied biodegradation of sol-gel mesoporous 
silica microparticles and showed that silica microparticles 
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are rapidly degraded in physiological buffer. Further, the 
authors demonstrated that addition of plasma proteins to 
the buffer retarded biodegradation by 20%–30%. It follows 
that biodegradation in vivo might be slower than in the in 
vitro setting.
With regard to the in vivo biodegradation data, the silicon 
content in the liver at different times after intravenous silica 
nanoparticle infusion is shown in Figure 3. The normal silicon 
content in the liver of control rats averaged 4.4 ± 1.55 µg/g. 
At one hour after silica nanoparticle infusion, the silicon 
content increased up to 282.3 ± 62.65 µg/g. Ten and 20 days 
after infusion, the silicon content in the liver was significantly 
lower (81.5 ± 9.25 and 30.2 ± 7.48 µg/g, respectively). These 
dynamics of silica nanoparticle dissolution are consistent 
with the data obtained in the in vitro model. However, at 
30 days following silica nanoparticle administration, we did 
not see any additional decrease in liver tissue silicon content 
(31.5 ± 11.87 µg/g), which might have been because of the 
higher stability of the intracellular pool of silica nanoparticles 
produced as a result of phagocytosis by Kupffer cells and, 
to a lesser extent, internalization of silica nanoparticles into 
hepatocytes and other liver cells. However, it remains unclear 
whether this increased silicon content in hepatic cells affects 
liver function or not.
Biodistribution of silica nanoparticles
In the controls, the silicon content was found to be 
significantly higher in myocardial tissue than in the liver 
(32 ± 2.8 versus 4 ± 2.3 µg/g, respectively, P , 0.05, 
Figure 4). The physiological process involved is currently 
unknown. Administration of silica nanoparticles to the 
sham-operated rats resulted in a dramatic rise in liver silicon 
content as compared with controls (163 ± 19.5 versus 
4 ± 2.3 µg/g, respectively, P , 0.01), while the myocardial 
silicon concentration remained unaffected (27 ± 9.7 versus 
32 ± 2.8 µg/g, respectively, P . 0.05). Administration of 
silica nanoparticles to the animals with cardiac ischemia-
reperfusion injury was associated with a significant increase 
in myocardial silicon content in comparison with the 
sham-operated animals (125 ± 28.2 versus 32 ± 2.8  µg/g, 
respectively, P , 0.05). Thus, the first evidence that 
nonmodified silica nanoparticles can accumulate within the 
anatomical area at risk after regional myocardial ischemia-
reperfusion was provided in this study.
Effects of silica nanoparticle-bound  
and free adenosine on blood pressure 
and infarct size
The data for mean blood pressure values are shown in Table 1. 
The extent of the blood pressure decrease was significantly 
less marked when adenosine was immobilized on the surface 
of the nanoparticles (Figure 5). The final series of experiments 
focused on investigation of the effect of free adenosine and 
nanoparticle-bound adenosine on infarct size. There were no 
differences in size of the risk area between the groups (Figure 6). 
Adenosine infusion caused a significant reduction in infarct 
size as compared with controls (29 ± 6.2 versus 63% ± 7.3%, 
respectively, P , 0.01). Administration of adenosine adsorbed 
onto the silica nanoparticles resulted in a further significant 
decrease in infarct size in comparison with free adenosine 
(18 ± 4.2 versus 29 ± 6.2%, respectively, P , 0.05).
Discussion
The major finding of this study is that adsorption of 
  adenosine onto silica nanoparticles enables passive delivery 
of adenosine to the ischemic-reperfused area of the heart, 
evidenced by more pronounced infarct size limitation and 
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attenuation of the hemodynamic side effects typical of the 
drug used.
Several groups of drugs with different mechanisms 
of action might potentially be targeted to the heart 
using nanosized carriers. G protein-coupled receptor 
agonists (eg, adenosine, bradykinin, opioids), activators 
of tyrosine kinase receptors (insulin, insulin-like growth 
factor-1, transforming growth factor-β1, erythropoietin), 
inhibitors of mitochondrial permeability transition pore 
(cyclosporine), and openers of ATP-sensitive potassium 
channels (nicorandil) are among the drugs used for 
pharmacological postconditioning in experimental and/or 
clinical studies. However, widespread clinical use of these 
drugs at doses required for a cardioprotective response 
is hampered by the high risk of dangerous side effects. 
For example, intravenous administration of adenosine is 
associated with arterial hypotension and bradycardia,20 while 
administration of bradykinin might lead to hypotension and 
bronchospasm.21 Cyclosporine, a mitochondrial permeability 
transition pore inhibitor, has been successfully used for 
pharmacological postconditioning in patients with acute 
ST elevation myocardial infarction.22 Cyclosporine is 
commonly used for immune suppression, and its prolonged 
use is associated with several side effects, including renal 
failure, hepatotoxicity, infection, and increased risk of tumor 
development. Thus, it is of prime importance to develop the 
technique of targeted delivery of cyclosporine to the ischemic 
heart which may help to attenuate its systemic toxicity.
At present, some experimental data are available on 
targeting the heart using organic nanocarriers. In particular, 
antimyosin monoclonal antibody-doped liposomes 
containing ATP were administered to the isolated rat heart 
prior to global ischemia-reperfusion,11 which was associated 
with better postischemic contractile recovery. Intracoro-
nary infusion of nontargeted ATP-loaded liposomes before 
regional ischemia-reperfusion injury resulted in a significant 
reduction in infarct size as compared with controls in a rab-
bit model.23 One possible limitation of these studies is that 
drug-loaded nanocarriers were administered prior to isch-
emia instead of being administered at the end of ischemia 
or at the early stage of reperfusion. It seems justified that 
accumulation of nanoparticles in the myocardium is most 
intensive at the time of reperfusion. Therefore, one can also 
expect to achieve optimal myocardial protection when infus-
ing drug-loaded nanoparticles at this time. There are several 
lines of evidence in support of this notion. First, myocyte 
injury associated with exposure/expression of injury mark-
ers required for active targeting becomes more pronounced 
after reperfusion. Second, myocardial reperfusion initiates 
the inflammatory response associated with increased micro-
vascular permeability, the latter being a major prerequisite 
for passive targeting.24 Third, reperfusion is accompanied by 
reactive hyperemia, which may contribute to better delivery 
of nanocarriers to the target area.25 Fourth, the early stage 
of reperfusion itself contributes strongly to the development 
of irreversible myocardial injury.2 Hence, release of the 
nanoparticle payload during this narrow time interval may 
prevent or block some of the mechanisms of lethal reperfu-
sion injury. Thus, in order to optimize the pharmacokinetic 
profile of a heart-targeted drug delivery system, it should 
be administered at the final stages of ischemia or at the very 
beginning of reperfusion.
250
10 min iv ADO + SNP
300 µg/kg × min 
10 min iv ADO
300 µg/kg × min 
10 min iv ADO
300 µg/kg × min 
Baseline Recovery Recovery
0
Figure 5 Representative blood pressure recording showing different blood pressure response to free and silica nanoparticle-bound adenosine. Initial free adenosine infusion 
was followed by recovery period and infusion of silica nanoparticle-bound adenosine. After recovery, one more episode of adenosine infusion was performed. 
Abbreviations: ADO, adenosine; SNP, silica nanoparticles.
Table 1 Mean blood pressure in the course of infusion of free adenosine and silica nanoparticle-bound adenosine
Mean blood pressure,  
mmHg
Baseline 5 min infusion 10 min infusion 5 min recovery 10 min recovery
Free ADO 125 ± 12   82 ± 7   85 ± 9 128 ± 5 119 ± 13
ADO + SNP 131 ± 8 108 ± 14* 113 ± 11* 134 ± 12 130 ± 10
Notes: Values are means ± standard deviation (SD). *P , 0.05 vs free adenosine. 
Abbreviations: ADO, adenosine; SNP, silica nanoparticles.
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In the study reported by Scott et al,10 vascular endothelial 
growth factor-loaded liposomes functionalized with 
monoclonal antibodies against P-selectin were administered 
intravenously to rats after permanent coronary artery ligation. 
The investigators showed increased capillary density within 
the infarct area 4 weeks after infarction and better post-infarct 
left ventricular function. Despite these positive findings, it is 
difficult to extrapolate the results of this study to current 
clinical practice because it was performed using a permanent 
ischemia model without reperfusion. At the same time, 
the current gold standard for treatment of acute coronary 
syndrome is prompt myocardial revascularization. Further, 
the benefits of this treatment regimen might be explained 
more by improved neovascularization of the peri-infarct 
area, and not by direct prevention of cardiac myocyte death 
within the ischemic area.
Important results were obtained in a landmark study 
by Takahama et al20 who used liposomal adenosine for 
treatment of myocardial ischemia-reperfusion injury in rats. 
Adenosine-loaded liposomes were infused intravenously 
for 10 minutes, starting 5 minutes prior to myocardial 
reperfusion. Selective accumulation of liposomes within 
the ischemic-reperfused area was confirmed using electron 
microscopy, optical fluorescence, and radionuclide 
imaging. In addition, liposomal adenosine administration 
was associated with more significant infarct size limitation 
and less severe arterial hypotension as compared with 
treatment using free adenosine. Taken together, our data 
are in agreement with these results. At the same time, 
there are several major differences in the characteristics 
of the carrier. In our study, we demonstrated for the first 
time that inorganic nanoparticles with a small diameter 
of 6–13 nm could be used for targeted drug delivery to 
the ischemic-reperfused heart. There are several potential 
advantages of silica nanoparticles compared with other drug 
nanocarriers. Different strategies for drug immobilization 
on the surface of the silica nanoparticles could be used, 
which may predetermine the different pattern of release 
required for optimal effect. There are at least three known 
methods, ie, covalent binding of the drug to the functional 
group of the spacer molecule engrafted on the surface 
of the functionalized silica, ionic immobilization, and 
physical adsorption. Further, several drugs with different 
mechanism(s) of action and distinct chemical structure can 
be immobilized on the surface of the silica nanoparticles 
at varying ratios. Lastly, silica nanomaterials are relatively 
inexpensive, with a long history of successful chemical 
modification and functionalization.26
An important question related to the potential use of silica 
nanoparticles in medical applications is particle toxicity. In 
cell culture experiments, mesoporous silica nanoparticles 
have been shown to have no injurious effect on viability 
and plasma membrane integrity,26 which is consistent with 
our acute experiments in vivo.12 With regard to long-term 
trials, the toxicity issue remains controversial. Kumar et al27 
in nude mice experiments showed complete clearance of 
organically modified 20–25 nm silica nanoparticles from the 
organism via hepatobiliary excretion within 15 days after a 
single intravenous infusion, with no sign of organ toxicity. 
In contrast, Xie et al,28 in a partially analogous experimental 
setting, demonstrated extensive liver injury, ie, hepatocyte 
necrosis and mononuclear infiltration, accompanied by 
retention of the silica nanoparticles in the reticuloendothelial 
system for over 30 days. The hepatotoxic effect after either 
single or repeated silica nanoparticle administration has 
also been reported by others.29,30 Differences in hepatotoxic 
effects, apart from other factors, might be accounted for 
by the distinct characteristics of particle size31 or surface 
charge,32 or both. Noteworthy, in our study, the liver silicon 
content in the silica nanoparticle-treated animals was 
documented to be at least six-fold higher than in the controls 
for up to 30 days after administration. Therefore, it seems 
that further experimentation is required to optimize both 
the dosage and physicochemical characteristics which can 
potentially provide better biodegradability.
In conclusion, silica nanoparticles are inert materials that 
might be used as carriers for heart-targeted drug delivery. 
Immobilization of adenosine on the surface of silica 
nanoparticles resulted in enhancement of free adenosine-
mediated infarct size limitation in an animal model. Further, 
the hypotensive effect of adenosine was attenuated after its 
adsorption on silica nanoparticles. The technique of active 
adenosine targeting will be studied to identify an approach 
that might be potentially helpful in clinical practice.
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